NRX Pharmaceuticals, Inc. Logo

NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):
US0894821034 (+2 more)
LEI:
Country:
United States of America
Address:
1201 ORANGE STREET, 19801 WILMINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Telomir Pharmaceuticals, Inc. Logo
Developing an oral small molecule to reverse aging and treat age-related diseases.
United States of America
TELO
Tempest Therapeutics, Inc. Logo
Clinical-stage oncology company developing oral small molecule therapeutics to treat cancer.
United States of America
TPST
TENAX THERAPEUTICS, INC. Logo
Clinical-stage pharma developing novel therapies for cardiovascular and pulmonary diseases.
United States of America
TENX
Teva Pharmaceutical Industries Ltd. Logo
A leader in affordable generic drugs and innovative specialty treatments for complex diseases.
Israel
TEVA
Tevogen Bio Holdings Inc. Logo
Developing precision, off-the-shelf T cell therapies for cancer, infections, and neuro disorders.
United States of America
TVGN
TG THERAPEUTICS, INC. Logo
Commercializes B-cell therapies like BRIUMVI® for multiple sclerosis & autoimmune diseases.
United States of America
TGTX
Tharimmune, Inc. Logo
Clinical-stage biotech developing therapies for immunology, oncology, & opioid effects.
United States of America
THAR
THERAGEN ETEX CO.,LTD. Logo
A biotech firm offering gene analysis and developing personalized cancer drugs.
South Korea
066700
Theratechnologies Inc. Logo
Biopharma company commercializing therapies for multi-drug resistant HIV and lipodystrophy.
United States of America
THTX
Theravance Biopharma, Inc. Logo
Developing medicines for specialty respiratory and neurologic diseases like COPD.
United States of America
TBPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.